Advanced search
Publication Cover
Expert Review of Vaccines Volume 14, 2015 - Issue 6
Submit an article Journal homepage
849
Views
40
CrossRef citations to date
0
Altmetric
Vaccine Profile

Flucelvax (Optaflu) for seasonal influenza

Ilaria ManiniDepartment of Molecular and Developmental Medicine, University of Siena, Via Aldo Moro 3, 53100, Siena, Italy
,
Alexander DomnichDepartment of Health Sciences, University of Genoa, Via Pastore 1, 16132, Genoa, Italy
,
Daniela AmiciziaDepartment of Health Sciences, University of Genoa, Via Pastore 1, 16132, Genoa, Italy
,
Stefania RossiDepartment of Molecular and Developmental Medicine, University of Siena, Via Aldo Moro 3, 53100, Siena, Italy
,
Teresa PozziDepartment of Molecular and Developmental Medicine, University of Siena, Via Aldo Moro 3, 53100, Siena, Italy
,
Roberto GaspariniDepartment of Health Sciences, University of Genoa, Via Pastore 1, 16132, Genoa, Italy
,
Donatella PanattoDepartment of Health Sciences, University of Genoa, Via Pastore 1, 16132, Genoa, Italy
&
Emanuele MontomoliDepartment of Molecular and Developmental Medicine, University of Siena, Via Aldo Moro 3, 53100, Siena, Italy;VisMederi srl, Enterprise in Life Science, Via Fiorentina 1, 53100, Siena, ItalyCorrespondence[email protected]
 show all
Pages 789-804 | Published online: 12 May 2015

Citations (40)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (10)

Jiayou Zhang, Zhenyu Qiu, Siya Wang, Zhenbin Liu, Ziling Qiao, Jiamin Wang, Kai Duan, Xuanxuan Nian, Zhongren Ma & Xiaoming Yang. (2023) Suspended cell lines for inactivated virus vaccine production. Expert Review of Vaccines 22:1, pages 468-480.
Read now
Alexander Domnich, Daniela Amicizia, Piero Luigi Lai, Matilde Ogliastro, Maria Piedrahita-Tovar, Andrea Orsi, Giancarlo Icardi & Donatella Panatto. (2023) Three seasons of enhanced safety surveillance of a cell culture-based quadrivalent influenza vaccine. Human Vaccines & Immunotherapeutics 19:2.
Read now
Chia-Chun Lai, Tsai-Chuan Weng, Po-Ling Chen, Yu-Fen Tseng, Chun-Yang Lin, Min-Yuan Chia, Wang-Chou Sung, Min-Shi Lee & Alan Yung-Chih Hu. (2020) Development and characterization of standard reagents for cell-based prepandemic influenza vaccine products. Human Vaccines & Immunotherapeutics 16:9, pages 2245-2251.
Read now
Claudia Maria Trombetta, Serena Marchi, Ilaria Manini, Giacomo Lazzeri & Emanuele Montomoli. (2019) Challenges in the development of egg-independent vaccines for influenza. Expert Review of Vaccines 18:7, pages 737-750.
Read now
Cecilia Trucchi, Chiara Paganino, Daniela Amicizia, Andrea Orsi, Valentino Tisa, Maria Francesca Piazza, Giancarlo Icardi & Filippo Ansaldi. (2019) Universal influenza virus vaccines: what needs to happen next?. Expert Opinion on Biological Therapy 19:7, pages 671-683.
Read now
Claudia Maria Trombetta, Elena Gianchecchi & Emanuele Montomoli. (2018) Influenza vaccines: Evaluation of the safety profile. Human Vaccines & Immunotherapeutics 14:3, pages 657-670.
Read now
Esteban Cruz, Joel Cain, Ben Crossett & Veysel Kayser. (2018) Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry. Human Vaccines & Immunotherapeutics 14:3, pages 508-517.
Read now
Sai V Vemula, Ekramy E Sayedahmed, Suryaprakash Sambhara & Suresh K Mittal. (2017) Vaccine approaches conferring cross-protection against influenza viruses. Expert Review of Vaccines 16:11, pages 1141-1154.
Read now
Nicola Luigi Bragazzi, Andrea Orsi, Filippo Ansaldi, Roberto Gasparini & Giancarlo Icardi. (2016) Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview. Human Vaccines & Immunotherapeutics 12:10, pages 2616-2627.
Read now
Claudia Maria Trombetta & Emanuele Montomoli. (2016) Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert Review of Vaccines 15:8, pages 967-976.
Read now

Articles from other publishers (30)

Di Yang, Lingwei Huang, Jiamin Wang, Huihao Wu, Zhenbin Liu, Ayimuguli Abudureyimu & Zilin Qiao. (2023) Tumorigenesis mechanism and application strategy of the MDCK cell line: A systematic review. Biologicals 83, pages 101699.
Crossref
Zhenbin Liu, Mengyuan Pei, Geng Liu, Zhenyu Qiu, Siya Wang, Zilin Qiao, Jiamin Wang, Dongwu Jin, Jiayou Zhang, Kai Duan, Xuanxuan Nian, Zhongren Ma & Xiaoming Yang. (2023) CDC20 is a potential target gene to inhibit the tumorigenesis of MDCK cells. Biologicals 83, pages 101697.
Crossref
Alexander Pralow, Marcus Hoffmann, Terry Nguyen‐Khuong, Markus Pioch, René Hennig, Yvonne Genzel, Erdmann Rapp & Udo Reichl. (2021) Comprehensive N ‐glycosylation analysis of the influenza A virus proteins HA and NA from adherent and suspension MDCK cells . The FEBS Journal 288:16, pages 4869-4891.
Crossref
Sofia B. Carvalho, Cristina Peixoto, Manuel J. T. Carrondo & Ricardo J. S. Silva. (2021) Downstream processing for influenza vaccines and candidates: An update. Biotechnology and Bioengineering 118:8, pages 2845-2869.
Crossref
Kannan Damodharan, Gandarvakottai Senthilkumar Arumugam, Suresh Ganesan, Mukesh Doble & Sathiah Thennarasu. (2021) A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2. RSC Advances 11:33, pages 20006-20035.
Crossref
Saborni Chakraborty, Vamsee Mallajosyula, Cristina M. Tato, Gene S. Tan & Taia T. Wang. (2021) SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. Advanced Drug Delivery Reviews 172, pages 314-338.
Crossref
Liqi Liu, Zi Li, Jianfang Zhou, Jian Lu, Xiyan Li, Jia Liu, Ning Xiao & Dayan Wang. (2021) The effect of single amino acid substitution at position 220 in the hemagglutinin glycoprotein on avian influenza H7N9 candidate vaccine virus. Virus Genes 57:2, pages 164-171.
Crossref
Sabine Pech, Markus Rehberg, Robert Janke, Dirk Benndorf, Yvonne Genzel, Thilo Muth, Albert Sickmann, Erdmann Rapp & Udo Reichl. (2021) Tracking changes in adaptation to suspension growth for MDCK cells: cell growth correlates with levels of metabolites, enzymes and proteins. Applied Microbiology and Biotechnology 105:5, pages 1861-1874.
Crossref
Milan Ganguly, Leena Yeolekar, Parikshit Tyagi, Umesh Sagar, Swapnil Narale, Yashodhan Anaspure, Sham Tupe, Kuntinath Wadkar, Nilesh Ingle, Rajeev Dhere, Francesco B. Scorza & Kutub Mahmood. (2020) Evaluation of manufacturing feasibility and safety of an MDCK cell-based live attenuated influenza vaccine (LAIV) platform. Vaccine 38:52, pages 8379-8386.
Crossref
Sigrid Gouma, Seth J Zost, Kaela Parkhouse, Angela Branche, David J Topham, Sarah Cobey & Scott E Hensley. (2020) Comparison of Human H3N2 Antibody Responses Elicited by Egg-Based, Cell-Based, and Recombinant Protein–Based Influenza Vaccines During the 2017–2018 Season. Clinical Infectious Diseases 71:6, pages 1447-1453.
Crossref
K. A. Richards, S. Moritzky, I. Shannon, T. Fitzgerald, H. Yang, A. Branche, D. J. Topham, J. J. Treanor, J. Nayak & Andrea J. Sant. (2020) Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans. npj Vaccines 5:1.
Crossref
Ana Filipa Rodrigues, Paulo Fernandes, Tanja Laske, Rute Castro, Paula Marques Alves, Yvonne Genzel & Ana Sofia Coroadinha. (2020) Cell Bank Origin of MDCK Parental Cells Shapes Adaptation to Serum-Free Suspension Culture and Canine Adenoviral Vector Production. International Journal of Molecular Sciences 21:17, pages 6111.
Crossref
Marina Koroleva, Frances Batarse, Savannah Moritzky, Carole Henry, Francisco Chaves, Patrick Wilson, Florian Krammer, Katherine Richards & Andrea J. Sant. (2020) Heterologous viral protein interactions within licensed seasonal influenza virus vaccines. npj Vaccines 5:1.
Crossref
Elodie Desuzinges Mandon, Andrés Pizzorno, Aurélien Traversier, Anne Champagne, Marie Eve Hamelin, Bruno Lina, Guy Boivin, Emmanuel Dejean, Manuel Rosa-Calatrava & Anass Jawhari. (2020) Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection. Vaccine 38:2, pages 278-287.
Crossref
Sophie Buffin, Isabelle Peubez, Fabienne Barrière, Marie-Claire Nicolaï, Tenekua Tapia, Vipra Dhir, Eric Forma, Nicolas Sève & Isabelle Legastelois. (2019) Influenza A and B virus-like particles produced in mammalian cells are highly immunogenic and induce functional antibodies. Vaccine 37:46, pages 6857-6867.
Crossref
Sonja C. J. H. Chua, Hui Qing Tan, David Engelberg & Lina H. K. Lim. (2019) Alternative Experimental Models for Studying Influenza Proteins, Host–Virus Interactions and Anti-Influenza Drugs. Pharmaceuticals 12:4, pages 147.
Crossref
Chia-Chun Lai, Tsai-Chuan Weng, Yu-Fen Tseng, Jen-Ron Chiang, Min-Shi Lee & Alan Yung-Chih Hu. (2019) Evaluation of novel disposable bioreactors on pandemic influenza virus production. PLOS ONE 14:8, pages e0220803.
Crossref
Florian Krammer. (2019) The human antibody response to influenza A virus infection and vaccination. Nature Reviews Immunology 19:6, pages 383-397.
Crossref
Giuseppe A. Sautto, Greg A. Kirchenbaum & Ted M. Ross. (2018) Towards a universal influenza vaccine: different approaches for one goal. Virology Journal 15:1.
Crossref
Felix Broecker, Sean T. H. Liu, Weina Sun, Florian Krammer, Viviana Simon & Peter Palese. (2018) Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice. Journal of Virology 92:20.
Crossref
Haruka Momose, Eita Sasaki, Madoka Kuramitsu, Isao Hamaguchi & Takuo Mizukami. (2018) Gene expression profiling toward the next generation safety control of influenza vaccines and adjuvants in Japan. Vaccine 36:43, pages 6449-6455.
Crossref
Sophie A. Valkenburg, Nancy H. L. Leung, Maireid B. Bull, Li-meng Yan, Athena P. Y. Li, Leo L. M. Poon & Benjamin J. Cowling. (2018) The Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine. Frontiers in Immunology 9.
Crossref
Peter Pushko, Irina Tretyakova, Rachmat Hidajat, Xiangjie Sun, Jessica A. Belser & Terrence M. Tumpey. (2018) Multi-clade H5N1 virus-like particles: Immunogenicity and protection against H5N1 virus and effects of beta-propiolactone. Vaccine 36:29, pages 4346-4353.
Crossref
Amber M. SmithVictor C. Huber. (2018) The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza. Viral Immunology 31:2, pages 159-173.
Crossref
Ilaria Manini, Claudia Trombetta, Giacomo Lazzeri, Teresa Pozzi, Stefania Rossi & Emanuele Montomoli. (2017) Egg-Independent Influenza Vaccines and Vaccine Candidates. Vaccines 5:3, pages 18.
Crossref
M. Butler & U. Reichl. 2021. Advances in Glycobiotechnology. Advances in Glycobiotechnology 1 36 .
Jerry P. Weir & Marion F. Gruber. (2016) An overview of the regulation of influenza vaccines in the United States. Influenza and Other Respiratory Viruses 10:5, pages 354-360.
Crossref
Javier Diez-Domingo, Maurizio de Martino, Jose Garcia-Sicilia Lopez, Gian Vincenzo Zuccotti, Giancarlo Icardi, Alberto Villani, David Moreno-Perez, María Méndez Hernández, Javier Álvarez Aldeán, Ahmed Abdul Mateen, Igwebuike Enweonye, Richard de Rooij & Richa Chandra. (2016) Safety and tolerability of cell culture-derived and egg-derived trivalent influenza vaccines in 3 to <18-year-old children and adolescents at risk of influenza-related complications. International Journal of Infectious Diseases 49, pages 171-178.
Crossref
Pedro L. Moro, Scott Winiecki, Paige Lewis, Tom T. Shimabukuro & Maria Cano. (2015) Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax®) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013–2015. Vaccine 33:48, pages 6684-6688.
Crossref
Patricia E Fast & Josephine H Cox. (2015) An influenza vaccine pill—can we swallow it?. The Lancet Infectious Diseases 15:9, pages 992-993.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.